1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Molecular and clinicopathological characterization of luminal HER2-enriched breast cancer
(
- Master (Two yrs)
- 2021
-
Mark
A mixed clinicopathological and molecular proxy of homologous recombination deficiency in triple negative breast cancer
(
- Master (Two yrs)
-
Mark
Epigenetic regulation of Cancer Testis Antigens: candidate drivers of genomic instability in Triple Negative Breast Cancer
(
- Master (Two yrs)
- 2020
-
Mark
Pan-cancer validation of a lung-adenocarcinoma-derived gene-expression-based prognostic predictor
(
- Master (Two yrs)